Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
12. Dezember 2024 09:07 ET
|
Hofseth Biocare ASA
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") has today purchased 700,000 shares in HBC at an average price of NOK 1.202837 per share. As a...
Hofseth Biocare ASA: Commences the project for a second hydrolysis plant in Norway to triple capacity
05. Dezember 2024 03:00 ET
|
Hofseth Biocare ASA
Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis...
Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT
08. November 2024 02:15 ET
|
Hofseth Biocare ASA
HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
Hofseth Biocare ASA: CFO RESIGNATION
22. Oktober 2024 04:56 ET
|
Hofseth Biocare ASA
Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of Hofseth BioCare ASA (“HBC”) to pursue opportunities outside of the company. "I would like to thank Christel for her...
Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT
08. Oktober 2024 02:45 ET
|
Hofseth Biocare ASA
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...
Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT
23. August 2024 02:00 ET
|
Hofseth Biocare ASA
HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year. Adjusted for the sale of assets in the second quarter, sales revenues were NOK...
Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY
14. August 2024 07:09 ET
|
Hofseth Biocare ASA
Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in science-led marine nutrition, proudly announces compelling new findings from a recent study on the benefits of its enzymatically...
Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.
02. Juli 2024 03:00 ET
|
Hofseth Biocare ASA
Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate...
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
11. Juni 2024 03:00 ET
|
Hofseth Biocare ASA
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into...
Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
16. Mai 2024 02:00 ET
|
Hofseth Biocare ASA
The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17 % YoY. The underlying growth we are seeing is coming from both...